ES2882335T3 - Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 - Google Patents
Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 Download PDFInfo
- Publication number
- ES2882335T3 ES2882335T3 ES17821622T ES17821622T ES2882335T3 ES 2882335 T3 ES2882335 T3 ES 2882335T3 ES 17821622 T ES17821622 T ES 17821622T ES 17821622 T ES17821622 T ES 17821622T ES 2882335 T3 ES2882335 T3 ES 2882335T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- isopropyl
- amine
- pyridyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 ***C1*=*(*)NC(*)C1 Chemical compound ***C1*=*(*)NC(*)C1 0.000 description 4
- LHBYTJWKVBHQTL-UHFFFAOYSA-N CC(C)c(nc1C)c(c(Cl)c2)[n]1nc2Cl Chemical compound CC(C)c(nc1C)c(c(Cl)c2)[n]1nc2Cl LHBYTJWKVBHQTL-UHFFFAOYSA-N 0.000 description 1
- GUFRGLBRZLEPCL-UHFFFAOYSA-N CC(C)c(nc1C)c(c(NCC#N)c2)[n]1nc2Cl Chemical compound CC(C)c(nc1C)c(c(NCC#N)c2)[n]1nc2Cl GUFRGLBRZLEPCL-UHFFFAOYSA-N 0.000 description 1
- GYZRYUZWHRMLQS-UHFFFAOYSA-N CC/C=[O]/c(nncc1)c1-c1cc(NCc2n[n](C)cn2)c(c(C(C)C)n[n]2C)c2n1 Chemical compound CC/C=[O]/c(nncc1)c1-c1cc(NCc2n[n](C)cn2)c(c(C(C)C)n[n]2C)c2n1 GYZRYUZWHRMLQS-UHFFFAOYSA-N 0.000 description 1
- RXKFSWWPDUSPPI-UHFFFAOYSA-N CCC(C)c(nc1C)c(c(NCc2n[n](C)cn2)c2)[n]1nc2-c(cccn1)c1OCC Chemical compound CCC(C)c(nc1C)c(c(NCc2n[n](C)cn2)c2)[n]1nc2-c(cccn1)c1OCC RXKFSWWPDUSPPI-UHFFFAOYSA-N 0.000 description 1
- JLNKUZUBBRTYOA-UHFFFAOYSA-N CCOC(C(C(O)=O)NC(OC(C)(C)C)=O)=O Chemical compound CCOC(C(C(O)=O)NC(OC(C)(C)C)=O)=O JLNKUZUBBRTYOA-UHFFFAOYSA-N 0.000 description 1
- ULRLHEXGRUWQLQ-UHFFFAOYSA-N CCOC(C(C(OCC)=O)NC(OC(C)(C)C)=O)=O Chemical compound CCOC(C(C(OCC)=O)NC(OC(C)(C)C)=O)=O ULRLHEXGRUWQLQ-UHFFFAOYSA-N 0.000 description 1
- CSIIVTYLKGCZSL-UHFFFAOYSA-N CCOc(nccc1)c1-c(cc1NCc2ccccn2)n[n]2c1c(C(C)C)nc2C Chemical compound CCOc(nccc1)c1-c(cc1NCc2ccccn2)n[n]2c1c(C(C)C)nc2C CSIIVTYLKGCZSL-UHFFFAOYSA-N 0.000 description 1
- WYHCKHHDBOXJTM-UHFFFAOYSA-N CCOc(nccc1)c1-c1cc(NCc2c[o]c(C)n2)c(c(C(C)C)n[n]2C)c2n1 Chemical compound CCOc(nccc1)c1-c1cc(NCc2c[o]c(C)n2)c(c(C(C)C)n[n]2C)c2n1 WYHCKHHDBOXJTM-UHFFFAOYSA-N 0.000 description 1
- JKBOBLRMRADSDW-UHFFFAOYSA-N CCOc(nccc1)c1-c1cc(NCc2n[nH]c(C)c2)c(c(C(C)C)n[n]2C)c2n1 Chemical compound CCOc(nccc1)c1-c1cc(NCc2n[nH]c(C)c2)c(c(C(C)C)n[n]2C)c2n1 JKBOBLRMRADSDW-UHFFFAOYSA-N 0.000 description 1
- UHUNWIYBXRPDQW-UHFFFAOYSA-N CCOc(nccc1)c1-c1nc([n](C)nc2C(C)C)c2c(NCc2n[n](C)nn2)c1 Chemical compound CCOc(nccc1)c1-c1nc([n](C)nc2C(C)C)c2c(NCc2n[n](C)nn2)c1 UHUNWIYBXRPDQW-UHFFFAOYSA-N 0.000 description 1
- VKLLORYFRGIAKH-UHFFFAOYSA-N CCOc1ncccc1-c(cc1NCc(cc2)ccc2OC)n[n]2c1c(C(C)=C)nc2C Chemical compound CCOc1ncccc1-c(cc1NCc(cc2)ccc2OC)n[n]2c1c(C(C)=C)nc2C VKLLORYFRGIAKH-UHFFFAOYSA-N 0.000 description 1
- UMKIWLULAMMBPJ-UHFFFAOYSA-N CCOc1ncccc1-c1cc(N(Cc2n[n](C)nc2)Cc(cc2)ccc2OC)c(c(C(C)C)n[n]2C)c2n1 Chemical compound CCOc1ncccc1-c1cc(N(Cc2n[n](C)nc2)Cc(cc2)ccc2OC)c(c(C(C)C)n[n]2C)c2n1 UMKIWLULAMMBPJ-UHFFFAOYSA-N 0.000 description 1
- RJXGGVCAZKTLDK-UHFFFAOYSA-N CCOc1ncccc1-c1cc(NCc2n[n](C)nc2)c(c(C(C)C)n[n]2C)c2n1 Chemical compound CCOc1ncccc1-c1cc(NCc2n[n](C)nc2)c(c(C(C)C)n[n]2C)c2n1 RJXGGVCAZKTLDK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600784 | 2016-12-22 | ||
| DKPA201700404 | 2017-07-06 | ||
| PCT/EP2017/083721 WO2018115067A1 (en) | 2016-12-22 | 2017-12-20 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2882335T3 true ES2882335T3 (es) | 2021-12-01 |
Family
ID=60812077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17821622T Active ES2882335T3 (es) | 2016-12-22 | 2017-12-20 | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10351561B2 (enExample) |
| EP (1) | EP3558988B1 (enExample) |
| JP (1) | JP7074758B2 (enExample) |
| KR (1) | KR20190095301A (enExample) |
| CN (1) | CN110099901B (enExample) |
| AU (1) | AU2017384481A1 (enExample) |
| BR (1) | BR112018017067A2 (enExample) |
| CA (1) | CA3046588A1 (enExample) |
| CL (1) | CL2019001669A1 (enExample) |
| CO (1) | CO2019005538A2 (enExample) |
| CR (1) | CR20190302A (enExample) |
| DO (1) | DOP2019000169A (enExample) |
| EC (1) | ECSP19043790A (enExample) |
| ES (1) | ES2882335T3 (enExample) |
| IL (1) | IL267561A (enExample) |
| JO (1) | JOP20190126A1 (enExample) |
| MX (1) | MX2019007509A (enExample) |
| PE (1) | PE20191323A1 (enExample) |
| PH (1) | PH12019501324A1 (enExample) |
| RU (1) | RU2019116251A (enExample) |
| TW (1) | TW201829405A (enExample) |
| WO (1) | WO2018115067A1 (enExample) |
| ZA (1) | ZA201904236B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| RU2020118913A (ru) | 2017-12-14 | 2022-01-14 | Х. Лундбекк А/С (H. Lundbeck A/S) | Виды комбинированного лечения, предусматривающего введение 1h-пиразолo[4,3-b]пиридинов |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| CN115151550B (zh) * | 2019-12-23 | 2024-11-22 | 桑福德·伯纳姆·普雷比医学发现研究所 | 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326379B1 (en) * | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| ES2319797T3 (es) * | 2004-07-05 | 2009-05-12 | Astellas Pharma Inc. | Derivados de pirazolopiridina. |
| US7652035B2 (en) | 2004-10-19 | 2010-01-26 | Neurocrine Bioscience, Inc. | CRF receptor antagonists and methods relating thereto |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN103497185A (zh) | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
| WO2009067607A2 (en) * | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| CN102223799A (zh) * | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
| JP6100883B2 (ja) | 2012-03-19 | 2017-03-22 | アビデ セラピューティクス，インク． | カルバマート化合物、及びその製造並びに使用 |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| US20180044343A1 (en) | 2015-03-16 | 2018-02-15 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| US20160311831A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as PDE1 Inhibitors |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| EP3436083A4 (en) | 2016-03-28 | 2019-11-27 | Intra-Cellular Therapies, Inc. | NOVEL COMPOSITIONS AND METHOD |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
-
2017
- 2017-06-16 JO JOP/2019/0126A patent/JOP20190126A1/ar unknown
- 2017-12-19 TW TW106144606A patent/TW201829405A/zh unknown
- 2017-12-20 AU AU2017384481A patent/AU2017384481A1/en not_active Abandoned
- 2017-12-20 CN CN201780079553.2A patent/CN110099901B/zh not_active Expired - Fee Related
- 2017-12-20 CR CR20190302A patent/CR20190302A/es unknown
- 2017-12-20 BR BR112018017067A patent/BR112018017067A2/pt not_active Application Discontinuation
- 2017-12-20 JP JP2019534197A patent/JP7074758B2/ja active Active
- 2017-12-20 ES ES17821622T patent/ES2882335T3/es active Active
- 2017-12-20 PE PE2019001294A patent/PE20191323A1/es unknown
- 2017-12-20 WO PCT/EP2017/083721 patent/WO2018115067A1/en not_active Ceased
- 2017-12-20 RU RU2019116251A patent/RU2019116251A/ru not_active Application Discontinuation
- 2017-12-20 CA CA3046588A patent/CA3046588A1/en not_active Abandoned
- 2017-12-20 MX MX2019007509A patent/MX2019007509A/es unknown
- 2017-12-20 EP EP17821622.2A patent/EP3558988B1/en active Active
- 2017-12-20 KR KR1020197017840A patent/KR20190095301A/ko not_active Ceased
- 2017-12-21 US US15/849,798 patent/US10351561B2/en active Active
-
2019
- 2019-05-28 CO CONC2019/0005538A patent/CO2019005538A2/es unknown
- 2019-05-29 US US16/424,585 patent/US10689379B2/en active Active
- 2019-06-11 PH PH12019501324A patent/PH12019501324A1/en unknown
- 2019-06-17 CL CL2019001669A patent/CL2019001669A1/es unknown
- 2019-06-18 DO DO2019000169A patent/DOP2019000169A/es unknown
- 2019-06-19 EC ECSENADI201943790A patent/ECSP19043790A/es unknown
- 2019-06-20 IL IL267561A patent/IL267561A/en unknown
- 2019-06-27 ZA ZA2019/04236A patent/ZA201904236B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017384481A1 (en) | 2019-06-13 |
| PH12019501324A1 (en) | 2019-09-16 |
| JP2020502230A (ja) | 2020-01-23 |
| MX2019007509A (es) | 2019-09-04 |
| PE20191323A1 (es) | 2019-09-24 |
| RU2019116251A (ru) | 2021-01-22 |
| EP3558988A1 (en) | 2019-10-30 |
| US20190352302A1 (en) | 2019-11-21 |
| WO2018115067A1 (en) | 2018-06-28 |
| CN110099901A (zh) | 2019-08-06 |
| CN110099901B (zh) | 2023-01-03 |
| CO2019005538A2 (es) | 2019-06-11 |
| CR20190302A (es) | 2019-08-21 |
| TW201829405A (zh) | 2018-08-16 |
| CA3046588A1 (en) | 2018-06-28 |
| KR20190095301A (ko) | 2019-08-14 |
| JP7074758B2 (ja) | 2022-05-24 |
| CL2019001669A1 (es) | 2019-09-06 |
| IL267561A (en) | 2019-08-29 |
| DOP2019000169A (es) | 2019-07-31 |
| US10689379B2 (en) | 2020-06-23 |
| ZA201904236B (en) | 2020-12-23 |
| EP3558988B1 (en) | 2021-07-07 |
| US10351561B2 (en) | 2019-07-16 |
| US20180179200A1 (en) | 2018-06-28 |
| ECSP19043790A (es) | 2019-06-30 |
| JOP20190126A1 (ar) | 2019-05-28 |
| RU2019116251A3 (enExample) | 2021-03-31 |
| BR112018017067A2 (pt) | 2019-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2882335T3 (es) | Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de PDE1 | |
| ES2784655T3 (es) | 1H-pirazolo[4,3-b]piridinas como inhibidores de PDE1 | |
| ES2898698T3 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa Rho (ROCK) | |
| US12109198B2 (en) | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | |
| ES2910623T3 (es) | 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1 | |
| BR112019017058A2 (pt) | compostos como inibidores de pde1, composição farmacêutica e uso dos mesmos | |
| ES2899868T3 (es) | Tratamientos de combinación que comprenden la administración de 1H-pirazolo[4,3-b]piridinas | |
| ES2900561T3 (es) | Tratamientos de combinación que comprenden la administración de 1H-pirazolo[4,3-b]piridinas | |
| CN111511742A (zh) | 作为PDE1抑制剂的吡唑并[3,4-b]吡啶和咪唑并[1,5-b]哒嗪 | |
| TW202509019A (zh) | Sarm1調節子、其製劑及用途 | |
| CA3213823A1 (en) | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof | |
| HK40011732B (en) | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors | |
| HK40011732A (en) | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |